Cargando…
Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
SIMPLE SUMMARY: Classic Hodgkin lymphoma (cHL) has a high cure rate with chemotherapy, but 10–30% of patients experience relapse or refractory (R/R) disease, depending on stage and risk factors. Treatment for R/R cHL differs between young, fit patients who are eligible for high-dose chemotherapy and...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526852/ https://www.ncbi.nlm.nih.gov/pubmed/37760478 http://dx.doi.org/10.3390/cancers15184509 |